Generalized eczema secondary to treatment with peginterferon alpha an ribavirin in two patients

E Díez Recio; C  Sánchez Herreros; P Belmar Flores; A Vergara Sánchez; E de Eusebio Murillo

2010, Number 3

<< Back Next >>

Med Cutan Iber Lat Am 2010; 38 (3)

Generalized eczema secondary to treatment with peginterferon alpha an ribavirin in two patients

Díez RE, Sánchez HC, Belmar FP, Vergara SA, Eusebio ME

Full text

How to cite this article

Language: Spanish
References: 11
Page: 117-120
PDF size: 120.66 Kb.

ABSTRACT

Treatment with interferon alpha or interferon alpha plus ribavirin in patients with chronic hepatitis C frequenty cause cutaneous local side effects limited to the injection sites. Distant or generalized eczematous reactions are rare. However, distant lesions may increase with the use of pegylated interferons alpha.

REFERENCES

McHutchinson JG, Gordon SC, Schiff ER, Schiffman ML, Lee WM, Rustgi VK et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment of chronic hepatitis C. N Engl J Med 1998; 339: 1485-92.
Paquet P, Pierard-Franchimont C, Arrese JE, Pierard GE. Effects indesirables cutanes des interferons. Rev Med Liege 2001; 56: 699- 702.
Jones GJ, Itri LM. Safety and tolerance of recombinant interferon alfa 2a (Roferon-A) in cancer patients. Cancer 1986; 57 (Supl. 8): 1709-15.
Fernández H, Requena L. Erupciones cutáneas medicamentosas. Ed Signament Edicions, SL. 2003.
Dereure O, Raison-Peyron N, Larrey D, Blanc F, Guilhou JJ. Diffuse inflammatory lesions in patients treated with interferon alfa and ribavirin for hepatitis C: a series of 20 patients. Br J Dermatol 2002; 147: 1142-6.
Guillot B, Blázquez L, Bessis D, Dereure O, Guilhou JJ. A prospective study of cutaneous adverse events induced by low dose alpha interferon treatment for malignant melanoma. Dermatology 2004; 208: 49-54.
Moore MM, Elpern DJ, Carter DJ. Severe, generalized nummular eczema secondary to interferon alfa-2b plus ribavirin combination therapy in a patient with chronic hepatitis C virus infection. Arch Dermatol 2004; 140: 215-7.
Manns MP, McHutchinson JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958- 65.
Cottoni F, Bolognini S, Deplano A, Garrucciu G, Manzoni NE, Careddu GF et al. Skin reaction in antiviral therapy for chronic hepatitis C: a role for polyethylene glycol interferon? Acta Derm Venereol 2004; 84: 20-3.
Vázquez-López F, Manjón-Haces JA, PérezÁlvarez R, Pérez-Oliva. Eczema-like lesions and disruption of therapy in patients treated with interferon alfa and ribavirin for chronic hepatitis C: the value of an interdisciplinary assessment. Br J Dermatol 2004; 150: 1028-54.
Ruiz de Casas A, García-Bravo B, Camacho F. Eczema generalizado secundario a tratamiento combinado con interferón alfa-2-a pegilado y ribavirina en un paciente con hepatitis crónica por virus de la hepatitis C. Actas Dermosifiliogr 2005; 96: 122-3.